NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

My greatest concern regarding DC-Vax-L was not that it didn’t work, but that it worked much better than expected. The crossover patients, combined with fewer control patients than planned, as well as other issues (pseudoprogression, etc) would render that statistical proof of efficacy to be muddled, even though patients were living longer than expected.

I didn’t believe the FDA to take a benevolent attitude in such an instance (mainly because of revolving door BP influence) but instead say “Wow, interesting results you got there but there are too many open questions as to what is really going on. Get back to us with another trial — I’m sure it will work out better next time.”

That, of course, would have killed the company.

With the revised SAP, this concern is gone.

And the stock price is just starting to reflect the new reality.